Use of ‘Click Chemistry’ for
the Synthesis of Tetrazole-Containing Analogues of the Neuroprotective
Agent Glycyl-<scp>l</scp>-prolyl-<scp>l</scp>-glutamic
Acid

Hung, Kuo-yuan; Harris, Paul W. R.; Brimble, Margaret A.

doi:10.1055/s-0028-1088128

Cited by 7 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GPE is not enzymatically stable and has a plasma half-life <5 min, requiring intravenous infusion for stable neuroprotection ( Batchelor et al, 2003 ). Trofinetide was discovered as an analog of GPE that improved proteolytic stability and bioavailability of the molecule ( Brimble et al, 2005 ; Harris et al, 2005 ; Lai et al, 2005 ; Trotter et al, 2005 ; Harris and Brimble, 2006 ; Bickerdike et al, 2009 ; Hung et al, 2009 ).…”

Section: Bench Research: Discovery Of Gpe Applicability In Rtt and De...mentioning

confidence: 99%

Development of trofinetide for the treatment of Rett syndrome: from bench to bedside

Kennedy,

Glass,

Glaze

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Rett syndrome (RTT) is rare neurodevelopmental disorder caused by mutations in the MECP2 gene that encodes methyl-CpG-binding protein 2 (MeCP2), a DNA-binding protein with roles in epigenetic regulation of gene expression. Functional loss of MeCP2 results in abnormal neuronal maturation and plasticity, characterized by loss of verbal communication and loss of fine and gross motor function, among others. Trofinetide, a synthetic analog of glycine-proline-glutamate, was approved by the US Food and Drug Administration for the treatment of RTT in adult and pediatric patients aged 2 years and older. Here, we present the development of trofinetide from bench research to clinical studies and emphasize how the collaboration between academia, the pharmaceutical industry, and patient advocacy led to the recent approval. The bench-to-bedside development of trofinetide underscores the value of collaboration between these groups in the development and approval of treatments for rare diseases.

show abstract

Section: Bench Research: Discovery Of Gpe Applicability In Rtt and De...mentioning

confidence: 99%

Development of trofinetide for the treatment of Rett syndrome: from bench to bedside

Kennedy,

Glass,

Glaze

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Other Five‐Membered Heterocycles

2011

Name Reactions in Heterocyclic Chemistry II

View full text Add to dashboard Cite

Thiazolidine-Protected β-Thiol Asparagine: Applications in One-Pot Ligation–Desulfurization Chemistry

et al. 2015

View full text Add to dashboard Cite

The synthesis of a β-thiol asparagine derivative bearing a novel (2,4,6-trimethoxyphenyl)thiazolidine protecting group is described. The efficient incorporation of the amino acid into the N-termini of peptides is demonstrated as well as the utility of the β-thiol asparagine moiety for rapid ligation reactions with peptide thioesters. The streamlined synthesis of native peptide products could be accomplished using a one-pot radical desulfurization of the β-thiol auxiliary following the ligation event. The utility of the amino acid is highlighted in the efficient one-pot assembly of the HIV entry inhibitor enfuvirtide.

show abstract

Use of ‘Click Chemistry’ for the Synthesis of Tetrazole-Containing Analogues of the Neuroprotective Agent Glycyl-l-prolyl-l-glutamic Acid

Cited by 7 publications

References 8 publications

Development of trofinetide for the treatment of Rett syndrome: from bench to bedside

Development of trofinetide for the treatment of Rett syndrome: from bench to bedside

Other Five‐Membered Heterocycles

Thiazolidine-Protected β-Thiol Asparagine: Applications in One-Pot Ligation–Desulfurization Chemistry

Contact Info

Product

Resources

About